Back to Faculty
Faculty

Marina Frimer

2026 Sessions

Recurrent Ovarian Cancer in the ADC Era: Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker vs Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

  • Moderator
    • Kathleen Moore
  • Presenter
    • Marina Frimer
    • Rebecca Porter
Gynecological Cancers

Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

  • Debate Speaker
    • Marina Frimer
Gynecological Cancers
Back to top